Targeting FGFR inhibition in cholangiocarcinoma

Author:

Goyal Lipika,Kongpetch SarinyaORCID,Crolley Valerie E.ORCID,Bridgewater JohnORCID

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Reference78 articles.

1. Cell lineage tracing reveals a biliary origin of intrahepatic cholangiocarcinoma;Guest;Cancer Res,2014

2. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma;Bridgewater;J Hepatol,2014

3. American Cancer Society. Survival Rates for Bile Duct Cancer Where do these numbers come from? 2020. https://www.cancer.org/cancer/bile-duct-cancer/detection-diagnosis-staging/survival-by-stage.html.

4. Cholangiocarcinoma 2020: the next horizon in mechanisms and management;Banales;Nat Rev Gastroenterol Hepatol,2020

5. Administration USF and D. FDA grants accelerated approval to pemigatinib for cholangiocarcinoma with an FGFR2 rearrangement or fusion. 2020. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pemigatinib-cholangiocarcinoma-fgfr2-rearrangement-or-fusion.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3